Cancer-Erythrocyte Membrane-Mimicking Fe<sub>3</sub>O<sub>4</sub> Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors

Yu, Kaixu; Chen, Ying; Zhang, Lu; Zheng, Yongqiang; Chen, Jinlin; Wang, Zhenhua; Yu, Xiaogang; Song, Kehan; Dong, Yimin; Xiong, Fanxiu; Dong, Zijian; Zhu, Hao; Sheng, Gaohong; Zhu, Meipeng; Yuan, Xi; Guan, Hanfeng; Xiong, Jiaqiang; Liu, Yi; Li, Feng

doi:10.1021/acsami.3c07379

Cited by 15 publications

(7 citation statements)

References 62 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common ideas include that ferroptotic stress inducing TAMs to repolarize from M2 type to M1 type [ 128 , 208 – 210 ], inducing ferroptosis of Tregs to reduce negative immune effect [ 127 ], targeting system Xc- to alleviate cystine deprivation in TME mediated by myeloid-derived suppressor cells (MDSCs) to promote T cell survival [ 211 ] and so on. Recently, Yu K et al designed a biomimetic hybrid cell membrane camouflaged by poly (lactic-co-glycolic) acid (PLGA)-loaded Fe 3 O 4 and DHJS (a probe for ROS generation) to induce ferroptosis in osteosarcoma cells, and successfully mediated macrophage M1 polarization as well as the infiltration of CD8 + T cells and dendritic cells in tumors [ 212 ]. However, in sarcomas with different immunophenotypes, the effects of ferroptosis on tumor immunity may be different and different kinds of ferroptosis inducers will also have different effects on immune cells and tumor cells [ 121 ].…”

Section: Progress Of Research On Ferroptosis In Sarcoma Treatmentmentioning

confidence: 99%

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Zeng,

Zhang,

Lin

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

Sarcoma is a malignant tumor that originates from mesenchymal tissue. The common treatment for sarcoma is surgery supplemented with radiotherapy and chemotherapy. However, patients have a 5-year survival rate of only approximately 60%, and sarcoma cells are highly resistant to chemotherapy. Ferroptosis is an iron-dependent nonapoptotic type of regulated programmed cell death that is closely related to the pathophysiological processes underlying tumorigenesis, neurological diseases and other conditions. Moreover, ferroptosis is mediated via multiple regulatory pathways that may be targets for disease therapy. Recent studies have shown that the induction of ferroptosis is an effective way to kill sarcoma cells and reduce their resistance to chemotherapeutic drugs. Moreover, ferroptosis-related genes are related to the immune system, and their expression can be used to predict sarcoma prognosis. In this review, we describe the molecular mechanism underlying ferroptosis in detail, systematically summarize recent research progress with respect to ferroptosis application as a sarcoma treatment in various contexts, and point out gaps in the theoretical research on ferroptosis, challenges to its clinical application, potential resolutions of these challenges to promote ferroptosis as an efficient, reliable and novel method of clinical sarcoma treatment.

show abstract

Section: Progress Of Research On Ferroptosis In Sarcoma Treatmentmentioning

confidence: 99%

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Zeng,

Zhang,

Lin

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…As a result, when their circulation behavior is replicated, these NPs have a better chance of reaching the targeted tumor site. Neutrophil membrane-coated NPs successfully transport themselves to tumor sites through neutrophil hitchhiking, utilizing their inherent affinity for tumors (Yu et al., 2023 ). This immunosuppressive microenvironment regulation enhances tumor immunotherapy’s efficacy as the NPs effectively navigate the immune cells (Yu et al., 2022 ).…”

Section: Applications Of Cell Membrane-based Nanoparticlesmentioning

confidence: 99%

Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective

Li,

Guo,

Zhong

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Nanotechnology has ignited a transformative revolution in disease detection, prevention, management, and treatment. Central to this paradigm shift is the innovative realm of cell membrane-based nanocarriers, a burgeoning class of biomimetic nanoparticles (NPs) that redefine the boundaries of biomedical applications. These remarkable nanocarriers, designed through a top-down approach, harness the intrinsic properties of cell-derived materials as their fundamental building blocks. Through shrouding themselves in natural cell membranes, these nanocarriers extend their circulation longevity and empower themselves to intricately navigate and modulate the multifaceted microenvironments associated with various diseases. This comprehensive review provides a panoramic view of recent breakthroughs in biomimetic nanomaterials, emphasizing their diverse applications in cancer treatment, cardiovascular therapy, viral infections, COVID-19 management, and autoimmune diseases. In this exposition, we deliver a concise yet illuminating overview of the distinctive properties underpinning biomimetic nanomaterials, elucidating their pivotal role in biomedical innovation. We subsequently delve into the exceptional advantages these nanomaterials offer, shedding light on the unique attributes that position them at the forefront of cutting-edge research. Moreover, we briefly explore the intricate synthesis processes employed in creating these biomimetic nanocarriers, shedding light on the methodologies that drive their development.

show abstract

“…[7,8] Thus, different approaches have been explored for ferroptosis-based tumor therapy. Fe 3 O 4 nanoparticles, [9,10] irondoped nanomaterials, [11,12] and iron-based nanomaterials-drug composites [13,14] have been developed to induce ferroptosis and cancer chemodynamic therapy. However, the limited penetration capacity of Fe ions of passive nanoparticles leads to unsatisfactory ferroptosis efficacy.…”

Section: Introductionmentioning

confidence: 99%

pH‐Sensitive Glucose‐Powered Nanomotors for Enhanced Intracellular Drug Delivery and Ferroptosis Efficiency

Ji,

Pan,

et al. 2023

Chemistry An Asian Journal

View full text Add to dashboard Cite

We propose a glucose‐powered Janus nanomotor where two faces are functionalized with glucose oxidase (GOx) and polydopamine‐Fe3+ chelates (PDF), respectively. In the glucose fuel solution, the GOx on the one side of these Janus nanomotors catalytically decomposes glucose fuels into gluconic acid and hydrogen peroxide (H2O2) to drive them at a speed of 2.67 μm/s. The underlying propulsion mechanism is the glucose‐based self‐diffusiophoresis owing to the generated local glucose concentration gradient by the enzymatic reaction. Based on the enhanced diffusion motion, such nanomotors with catalytic activity increase the contact probability towards cells and subsequently exhibit excellent capabilities for Fe3+ ions delivery and H2O2 generation for enhancing ferroptosis efficiency for inducing cancer cell death. In particular, the Fe3+ ions are released from nanomotors in a slightly acidic environment, and subsequently generate toxic hydroxyl radicals via Fenton reactions, which accumulation reactive oxygen species (ROS) level (~300%) and further lipid peroxidation (LPO) strengthened ferroptosis therapy for cancer treatment. Such a pH‐sensitive nanomotor with efficient diffusion can exhibit Fe ions overloading and sufficient H2O2 to promote ferroptosis efficiency, which provides great potential for future cancer precise therapy.

show abstract

Cancer-Erythrocyte Membrane-Mimicking Fe₃O₄ Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors

Cited by 15 publications

References 62 publications

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective

pH‐Sensitive Glucose‐Powered Nanomotors for Enhanced Intracellular Drug Delivery and Ferroptosis Efficiency

Contact Info

Product

Resources

About

Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors

Cited by 15 publications

References 62 publications

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects

Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective

pH‐Sensitive Glucose‐Powered Nanomotors for Enhanced Intracellular Drug Delivery and Ferroptosis Efficiency

Contact Info

Product

Resources

About

Cancer-Erythrocyte Membrane-Mimicking Fe₃O₄ Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors